Prevalence of AR‐V7 in CTC in mCRPC
•
Pre‐Enza, Pre‐Abi : 11.6%
•
Post‐Enza
only
: 25.0%
•
Post‐Abi
only
: 51.2%
•
Post‐Enza
and
Post‐Abi : 66.7%
S ll
b f
i
(62%)
ma num ers o pat ents
The role of other prior therapies and extent of disease
not ke ed in
y
Antonarakis et al. J Clin Oncol 2014; 32:5s: abstract 5001
Antonarakis ES, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014, 371(11):1028-38
